Citadel Advisors
ZYNE

Citadel Advisors’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Citadel Advisors’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-17,471
Closed -$9.21K – 15868
2022
Q4 		$9.26K Sell
17,471
-102,364
-85% -$64.9K ﹤0.01% 13696
2022
Q3 		$87K Buy
+119,835
New +$136K ﹤0.01% 11214
2022
Q2 		– Sell
-41,665
Closed -$53.1K – 14531
2022
Q1 		$86K Sell
41,665
-89,531
-68% -$213K ﹤0.01% 12423
2021
Q4 		$378K Buy
131,196
+53,353
+69% +$197K ﹤0.01% 10375
2021
Q3 		$330K Sell
77,843
-5,639
-7% -$25.2K ﹤0.01% 10863
2021
Q2 		$442K Sell
83,482
-128,388
-61% -$617K ﹤0.01% 10330
2021
Q1 		$985K Buy
211,870
+179,654
+558% +$814K ﹤0.01% 8155
2020
Q4 		$106K Buy
32,216
+3,534
+12% +$13.4K ﹤0.01% 10193
2020
Q3 		$95K Buy
28,682
+18,109
+171% +$66.5K ﹤0.01% 9297
2020
Q2 		$36K Sell
10,573
-5,893
-36% -$27.9K ﹤0.01% 9418
2020
Q1 		$63K Buy
16,466
+6,395
+63% +$29.7K ﹤0.01% 8918
2019
Q4 		$61K Buy
+10,071
New +$68.9K ﹤0.01% 8700
2018
Q4 		– Sell
-24,278
Closed -$133K – 9942
2018
Q3 		$198K Buy
+24,278
New +$186K ﹤0.01% 8225
2017
Q3 		– Sell
-458,331
Closed -$4.85M – 8198
2017
Q2 		$7.78M Buy
458,331
+121,704
+36% +$2.42M 0.01% 1668
2017
Q1 		$6.77M Buy
+336,627
New +$6.69M 0.01% 1749
2016
Q4 		– Sell
-16,677
Closed -$225K – 8014
2016
Q3 		$218K Buy
+16,677
New +$158K ﹤0.01% 6189

Other funds holding ZYNE

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
CM
Crystalline Management Montreal, Quebec, Canada $112M AUM 21.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors's ZYNE Position: Q1 2023 in Review

Citadel Advisors sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q1 2023, closing a stake of 17,471 shares — an estimated $9.21K sold.

Citadel Advisors first reported a position in ZYNE in Q3 2016 and held it in 16 quarters. The position peaked at $7.78M in Q2 2017. 44 funds tracked by Wall St. Rank hold ZYNE as of Q1 2023.

  • Citadel Advisors reported no remaining Zynerba Pharmaceuticals, Inc position as of Q1 2023 after selling out during the quarter.
  • Citadel Advisors sold 17,471 Zynerba Pharmaceuticals, Inc shares in Q1 2023, an estimated $9.21K.
  • Citadel Advisors first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2016 and held it in 16 quarters.
  • Citadel Advisors's Zynerba Pharmaceuticals, Inc position peaked at $7.78M in Q2 2017.
  • 44 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.